Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD
June 2nd 2025Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.